BRPI0411808A - formulações farmacêuticas de compostos para inibição de amilóide - Google Patents

formulações farmacêuticas de compostos para inibição de amilóide

Info

Publication number
BRPI0411808A
BRPI0411808A BRPI0411808-1A BRPI0411808A BRPI0411808A BR PI0411808 A BRPI0411808 A BR PI0411808A BR PI0411808 A BRPI0411808 A BR PI0411808A BR PI0411808 A BRPI0411808 A BR PI0411808A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
inhibiting compounds
amyloid
amyloid inhibiting
methods
Prior art date
Application number
BRPI0411808-1A
Other languages
English (en)
Inventor
Audley Legore
Original Assignee
Neurochem Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Int Ltd filed Critical Neurochem Int Ltd
Publication of BRPI0411808A publication Critical patent/BRPI0411808A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS DE COMPOSTOS PARA INIBIçãO DE AMILóIDE". São descritos formulações terapêuticas e métodos para inibir a deposição de amilóide em um indivíduo, qualquer que seja sua avaliação clínica. As formulações terapêuticas e métodos para prevenir ou tratar amiloidose e/ou doença relacionada ao amilóide são também descritos.
BRPI0411808-1A 2003-06-23 2004-06-21 formulações farmacêuticas de compostos para inibição de amilóide BRPI0411808A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48098403P 2003-06-23 2003-06-23
US51211603P 2003-10-17 2003-10-17
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
PCT/IB2004/002381 WO2004112762A2 (en) 2003-06-23 2004-06-21 Pharmaceutical formulations of amyloid inhibiting compounds

Publications (1)

Publication Number Publication Date
BRPI0411808A true BRPI0411808A (pt) 2006-08-08

Family

ID=33545348

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411808-1A BRPI0411808A (pt) 2003-06-23 2004-06-21 formulações farmacêuticas de compostos para inibição de amilóide

Country Status (18)

Country Link
US (2) US20050142191A1 (pt)
EP (2) EP2127648A1 (pt)
JP (1) JP4903561B2 (pt)
CN (1) CN103550196A (pt)
AT (1) ATE438391T1 (pt)
AU (2) AU2004248995B2 (pt)
BR (1) BRPI0411808A (pt)
CA (1) CA2529268C (pt)
DE (1) DE602004022408D1 (pt)
DK (1) DK1635799T3 (pt)
ES (1) ES2328818T3 (pt)
IL (1) IL172193A0 (pt)
MX (1) MXPA05013974A (pt)
NZ (1) NZ544685A (pt)
PL (1) PL1635799T3 (pt)
PT (1) PT1635799E (pt)
SI (1) SI1635799T1 (pt)
WO (1) WO2004112762A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4726304B2 (ja) * 1999-04-28 2011-07-20 ベルス ヘルス （インターナショナル） リミティッド アミロイドーシスを治療するための組成物および方法
CA2375628A1 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
MXPA05006940A (es) * 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
KR20070120190A (ko) * 2005-04-12 2007-12-21 뉴로켐 (인터내셔널) 리미티드 아밀로이드 억제 화합물의 제약 제제
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
DK2089417T3 (en) * 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
MX2009006768A (es) * 2006-12-22 2009-08-31 Bellus Health Int Ltd Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
WO2010040232A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
EP2944022B1 (en) 2013-01-08 2019-12-25 Rambus Inc. Integrated circuit comprising circuitry to determine settings for an injection-locked oscillator
RS64744B1 (sr) 2014-03-21 2023-11-30 Alzheon Inc Jedinjenja za upotrebu u lečenju alchajmerove bolesti kod pacijenata sa apoe4+/+
PL3347002T3 (pl) 2015-09-10 2023-11-13 Alzheon, Inc. Leczenie choroby alzheimera w konkretnej populacji pacjentów
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658966A (en) * 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
US3920833A (en) * 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0119274B1 (en) 1982-09-08 1986-11-26 MITSUI TOATSU CHEMICALS, Inc. Process for producing aminoalkylsulfonic acids
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP2642198B2 (ja) * 1989-08-24 1997-08-20 元庸 村上 胃粘膜障害治療剤
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
GB9117716D0 (en) 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
WO1993003714A2 (en) 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
CA2159326C (en) * 1993-03-29 2000-05-30 Robert Kisilevsky Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
ATE357221T1 (de) * 1994-04-22 2007-04-15 Astellas Pharma Inc Kolon-spezifisches arzneistofffreisetzungssystem
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
WO1997009925A2 (en) * 1995-09-12 1997-03-20 The General Hospital Corporation Method for early detection of ovarian cancer
AU703540B2 (en) 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
NZ568553A (en) 1998-02-11 2010-02-26 Bellus Health Int Ltd Treatment of inflammation, AB-induced cell toxicity, neuronal cell death or neuronal loss in subjects suffering from AlzheimerÆs disease
IL139688A0 (en) * 1998-05-15 2002-02-10 Neurochem Inc Use of amyloid inhibitors for modulating neuronal cell death
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
JP4726304B2 (ja) * 1999-04-28 2011-07-20 ベルス ヘルス （インターナショナル） リミティッド アミロイドーシスを治療するための組成物および方法
CA2375628A1 (en) 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
AU780624B2 (en) * 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
KR20080003945A (ko) * 1999-12-23 2008-01-08 뉴로겜 인터내셔널 리미티드 대뇌 아밀로이드 혈관병증을 조절하는 화합물 및 방법
US6376557B1 (en) * 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
FR2832928B1 (fr) * 2001-11-30 2004-02-06 Dermo Cosmologie Lab De Composition a base d'ester de diosgenine applicable par voie topique
JP4354180B2 (ja) * 2001-12-26 2009-10-28 武田薬品工業株式会社 軽度認知障害治療剤
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
MXPA05006940A (es) * 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid

Also Published As

Publication number Publication date
JP2007518672A (ja) 2007-07-12
AU2004248995B2 (en) 2010-01-07
ATE438391T1 (de) 2009-08-15
CN103550196A (zh) 2014-02-05
JP4903561B2 (ja) 2012-03-28
US20090182056A1 (en) 2009-07-16
EP1635799A2 (en) 2006-03-22
PT1635799E (pt) 2009-09-23
US20050142191A1 (en) 2005-06-30
SI1635799T1 (sl) 2009-12-31
EP2127648A1 (en) 2009-12-02
AU2010201299A1 (en) 2010-04-22
ES2328818T3 (es) 2009-11-18
NZ544685A (en) 2009-05-31
MXPA05013974A (es) 2006-03-09
AU2004248995A1 (en) 2004-12-29
CA2529268A1 (en) 2004-12-29
DE602004022408D1 (de) 2009-09-17
EP1635799B1 (en) 2009-08-05
US8835500B2 (en) 2014-09-16
IL172193A0 (en) 2009-02-11
CA2529268C (en) 2013-10-29
PL1635799T3 (pl) 2010-01-29
WO2004112762A3 (en) 2005-06-02
WO2004112762A2 (en) 2004-12-29
DK1635799T3 (da) 2009-11-23

Similar Documents

Publication Publication Date Title
IL172193A0 (en) Pharmaceutical formulations of amyloid inhibiting compounds
CY2014028I2 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
AR028285A1 (es) Medicamentos intracorporeos para tratamiento fotodinamico de enfermedad
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
IS7670A (is) Samsett meðferð fyrir offjölgunar sjúkdóma
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds
DK1614419T3 (da) Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
BRPI0606822A2 (pt) composto, métodos para preparar um composto e para tratar dor e/ou inflamação, composição farmacêutica, e, manufatura de um medicamento
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
ATE369136T1 (de) Therapeutische behandlung
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
NO20065196L (no) Terapeutisk kombinasjon for behandling av Alzheimers sykdom
IS8477A (is) Beta-laktöm til að meðhöndla MTK sjúkdóma
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BELLUS HEALTH (INTERNATIONAL) LIMITED (CH)

Free format text: NOME ALTERADO DE: NEUROCHEM (INTERNATIONAL) LIMITED

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]